EP0278474A1 — Electrolytic transdermal delivery of polypeptides
Assigned to Drug Delivery Systems Inc · Expires 1988-08-17 · 38y expired
What this patent protects
The invention comprises in combination: a) a polypeptide having from about three to about 20 peptide units in aqueous solution or suspension, and b) an electrolytic device (10) for transdermal transport of the polypeptide to the bloodstream of the patient. It may be use…
USPTO Abstract
The invention comprises in combination: a) a polypeptide having from about three to about 20 peptide units in aqueous solution or suspension, and b) an electrolytic device (10) for transdermal transport of the polypeptide to the bloodstream of the patient. It may be useful to enhance the transdermal delivery of the polypeptide by adding an aqueous cosolute/cosolvent with negative Setschenow constants. The electrolytic device preferably comprises a hydrophilic reservoir (24) containing a supply of the aqueous polypeptide solution or suspension, an electric battery (28), two extended contacts (26, 32), and optionally a semipermeable membrane (22) between the reservoir and the patient's skin. Representative polypeptides include oxytocin, angiotensin I, II, and III, substance P, vasopressin, lypressin, desmopressin, leuprolide acetate, antripeptin, and the like.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.